title: Protease inhibitors and decreased birth weight in HIV-infected pregnant women with impaired glucose tolerance.
abstract: OBJECTIVE
  To assess the impact of highly active antiretroviral therapy, including a protease inhibitor (HAART/PI), on maternal glucose tolerance and fetal growth.
  
  
  METHODS
  A retrospective chart review of pregnancy outcomes of human immunodeficiency virus-infected pregnant women receiving HAART/PI (n=41) or zidovudine monotherapy (n=23).
  
  
  RESULTS
  Abnormal 1-hour glucose tolerance tests (1hGTT) were observed in 30% of subjects receiving HAART/PI between 24 and 28 weeks' gestation. An elevated 1hGTT was associated with a significantly lower mean birth weight in subjects receiving HAART/PI compared to babies born to mothers with a normal 1hGTT (3.40+/-0.09 vs 3.00+/-0.18 kg, p<0.05, ANOVA).
  
  
  CONCLUSIONS
  HAART/PI therapy is associated with an increased rate of impaired glucose tolerance in pregnancy and impaired fetal growth. This finding merits further investigation.
authors.affiliation: Department of Reproductive Medicine, University of California San Diego, La Jolla, CA, USA.
authors.forename: Ramen
authors.initials: R
authors.lastname: Chmait
authors.forename: Patricia
authors.initials: P
authors.lastname: Franklin
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Spector
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Hull
mesh_terms: D000328:Adult; D023241:Antiretroviral Therapy, Highly Active; D001724:Birth Weight; D001786:Blood Glucose / Q000032:analysis*; D005260:Female; D005951:Glucose Tolerance Test; D015658:HIV Infections / Q000188:drug therapy / Q000503:physiopathology*; D006801:Humans; D007333:Insulin Resistance; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000503:physiopathology*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D001786:Blood Glucose; D011480:Protease Inhibitors